Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 6/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30558705 | 1.00 | HDAC1 (0.46) | HDAC1HDAC6ADORA2AP2RX7CXCR4 | |
| SCHEMBL1198594 | 0.91 | HDAC1 (0.39) | HDAC1HDAC6ADORA2AP2RX7 | |
| SCHEMBL29560239 | 0.91 | HDAC1 (0.39) | HDAC1HDAC6ADORA2AP2RX7 | |
| SCHEMBL12185906 | 0.85 | HDAC1 (0.43) | HDAC1HDAC6CXCR4MAPK1ALDH1A1 | |
| SCHEMBL29640806 | 0.84 | HDAC1 (0.45) | HDAC1HDAC6ADORA2AP2RX7CXCR4 | |
| SCHEMBL2688968 | 0.84 | HDAC1 (0.45) | HDAC1HDAC6ADORA2AP2RX7CXCR4 | |
| SCHEMBL3147432 | 0.82 | P2RX7 (0.38) | HDAC1HDAC6ADORA2AP2RX7ALDH1A1 | |
| SCHEMBL2597816 | 0.82 | HDAC1 (0.46) | HDAC1HDAC6ADORA2AP2RX7CXCR4 | |
| SCHEMBL27766407 | 0.81 | HDAC1 (0.44) | HDAC1HDAC6ADORA2AP2RX7CXCR4 | |
| SCHEMBL2305432 | 0.81 | HDAC1 (0.45) | HDAC1HDAC6ADORA2AP2RX7CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051360-A1 | SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2025-02-13 | — | — | US | disclosed |
| WO-2023116748-A1 | SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF | 广东东阳光药业有限公司 | 2023-06-29 | — | — | WO | disclosed |
| CN-116332961-A | Substituted heteroaryl compounds, compositions and uses thereof | 广东东阳光药业有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20100105915-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2010-04-29 | — | — | US | disclosed |
| US-7629337-B2 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| CN-101353324-A | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED INC (CA) | 2009-01-28 | — | — | CN | disclosed |
| US-7452994-B2 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED, INC. (CA) | 2008-11-18 | — | — | US | disclosed |
| US-7452994-B2 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED, INC. (CA) | 2008-11-18 | — | — | US | disclosed |
| US-7452994-B2 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED, INC. (CA) | 2008-11-18 | — | — | US | disclosed |
| CN-100412062-C | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED INC (CA) | 2008-08-20 | — | — | CN | disclosed |
| US-20050080267-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED, INC. (CA) | 2005-04-14 | — | — | US | disclosed |
| EP-1487795-A4 | SYNTHESIS OF ENANTIOMERICALLY PURE AMINO-SUBSTITUTED FUSED BICYCLIC RINGS | ANORMED INC (CA) | 2005-02-09 | — | — | EP | disclosed |
| EP-1487795-A2 | SYNTHESIS OF ENANTIOMERICALLY PURE AMINO-SUBSTITUTED FUSED BICYCLIC RINGS | ANORMED INC. (CA) | 2004-12-22 | — | — | EP | disclosed |
| US-6825351-B2 | SELECTIVE HYDROGENATION OF AMINO-SUBSTITUTED FUSED BICYCLIC AROMATIC RING SYSTEM, PREPARATION OF RACEMIC AMINO SUBSTITUTED FUSED BICYCLIC RING SYSTEM VIA NITROSATION, ENZYMATIC RESOLUTION OF RACEMIC MIXTURE TO PRODUCE (R)- AND (S)-FORMS | ANORMED, INC. (CA) | 2004-11-30 | — | — | US | disclosed |
| US-20040235823-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-11-25 | — | — | US | disclosed |
| US-6750348-B1 | PROTECTIVE EFFECTS AGAINST INFECTION BY HIV THROUGH BINDING TO CHEMOKINE RECEPTORS, INCLUDING CXCR4 AND CCR5;N-(2-PYRIDINYLMETHYL)-N'-(2-(PHENYLUREIDO)ETHYL)-N'-(5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-1,4-BENZENEDIMETHANAMINE | ANORMED, INC. (CA) | 2004-06-15 | — | — | US | disclosed |
| US-20030114679-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED CORPORATION (CA) | 2003-06-19 | — | — | US | disclosed |
| WO-2003022785-A2 | SYNTHESIS OF ENANTIOMERICALLY PURE AMINO-SUBSTITUTED FUSED BICYCLIC RINGS | ANORMED INC. (CA) | 2003-03-20 | — | — | WO | disclosed |
| EP-1163238-A1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000056729-A1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114679-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | CBR1, POR, CBR3 | HDAC1 2323/4885HDAC6 4303/4885ADORA2A 832/4885 |
| US-20100105915-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | CXCR4, CCR5, CXCR3 | HDAC1 836/4885HDAC6 1168/4885ADORA2A 230/4885 |
| US-20050080267-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | CBR1, POR, CBR3 | HDAC1 2323/4885HDAC6 4303/4885ADORA2A 832/4885 |
| US-20040235823-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR4, CXCR1 | HDAC1 1116/4885HDAC6 1089/4885ADORA2A 153/4885 |
| US-20250051360-A1 | SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF | TYK2, JAK2, JAK1 | HDAC1 1380/4885HDAC6 711/4885ADORA2A 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.